210 related articles for article (PubMed ID: 487815)
1. Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters.
Barfield A; Melo J; Coutinho E; Alvarez-Sanchez F; Faundes A; Brache V; Leon P; Frick J; Bartsch G; Weiske WH; Brenner P; Mishell D; Bernstein G; Ortiz A
Contraception; 1979 Aug; 20(2):121-7. PubMed ID: 487815
[TBL] [Abstract][Full Text] [Related]
2. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
3. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
Soufir JC; Jouannet P; Marson J; Soumah A
Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
[TBL] [Abstract][Full Text] [Related]
4. Spermatogenesis in men treated with injections of medroxyprogesterone acetate combined with testosterone enanthate.
Frick J; Danner C; Kunit G; Joos H; Köhle R
Int J Androl; 1982 Jun; 5(3):246-52. PubMed ID: 7118265
[TBL] [Abstract][Full Text] [Related]
5. Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception.
Knuth UA; Yeung CH; Nieschlag E
Fertil Steril; 1989 Jun; 51(6):1011-8. PubMed ID: 2524404
[TBL] [Abstract][Full Text] [Related]
6. Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men.
Pangkahila W
Int J Androl; 1991 Aug; 14(4):248-56. PubMed ID: 1831798
[TBL] [Abstract][Full Text] [Related]
7. The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. I. Uniform dosage levels.
Frick J; Bartsch G; Weiske WH
Contraception; 1977 Jun; 15(6):649-68. PubMed ID: 891192
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
Guerin JF; Rollet J
Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
[TBL] [Abstract][Full Text] [Related]
9. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
[TBL] [Abstract][Full Text] [Related]
10. Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive.
Brenner PF; Mishell DR; Bernstein GS; Ortiz A
Contraception; 1977 Jun; 15(6):679-91. PubMed ID: 891194
[TBL] [Abstract][Full Text] [Related]
11. Endocrinological and physiological features after steroid treatment of male rats.
Hunt DM; Lau IF; Saksena SK; Chang MC
Arch Androl; 1978 Sep; 1(4):311-20. PubMed ID: 736678
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.
Foegh M; Nicol K; Petersen IB; Schou G
Contraception; 1980 Jun; 21(6):631-40. PubMed ID: 6775869
[TBL] [Abstract][Full Text] [Related]
13. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
Matsumoto AM
J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
[TBL] [Abstract][Full Text] [Related]
14. The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme.
Bain J; Rachlis V; Robert E; Khait Z
Contraception; 1980 Apr; 21(4):365-79. PubMed ID: 6771093
[TBL] [Abstract][Full Text] [Related]
15. Is high dosage testosterone an effective male contraceptive agent?
Matsumoto AM
Fertil Steril; 1988 Aug; 50(2):324-8. PubMed ID: 3396702
[TBL] [Abstract][Full Text] [Related]
16. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
[TBL] [Abstract][Full Text] [Related]
17. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
Wallace EM; Gow SM; Wu FC
J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
[TBL] [Abstract][Full Text] [Related]
18. Use of low-dosage oral cyproterone acetate as a male contraceptive.
Wang C; Yeung KK
Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
[TBL] [Abstract][Full Text] [Related]
19. Suppression of human spermatogenesis by testosterone implants.
Handelsman DJ; Conway AJ; Boylan LM
J Clin Endocrinol Metab; 1992 Nov; 75(5):1326-32. PubMed ID: 1430094
[TBL] [Abstract][Full Text] [Related]
20. Suppression of sperm function by depot medroxyprogesterone acetate and testosterone enanthate in steroid male contraception.
Wu FC; Aitken RJ
Fertil Steril; 1989 Apr; 51(4):691-8. PubMed ID: 2522398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
